{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:46Z","timestamp":1786982146613,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Upper tract urothelial carcinoma (UTUC) is uncommon accounting for less than 10% of all urothelial tumours. Ureteroscopic management (URS) is the first line treatment for low-risk disease and has been increasingly utilised due to technological advances and increasing surgical experience. This review looks at patient outcomes relating to URS, emerging technologies and the role of adjuvant intracavitary therapy in the management of UTUC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>URS has firmly established itself in the management algorithm for UTUC, and a good body of evidence supports its use for low-risk disease, wherein oncological outcomes are comparable to traditional nephroureterectomy (RNU). Larger tumours can now be managed using URS with a lower morbidity than radical surgery, though with higher associated local recurrence rate and risk of progression to RNU, and as a result, patient selection and close surveillance remains key. There is limited evidence for adjuvant intracavitary therapy (Mitomycin C or BCG) in UTUC although the development of novel polymers and biodegradable stents may improve drug delivery to the upper urinary tract.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>URS has a clearly defined role in low-risk UTUC, and its use in larger tumours appears to be appropriate in a selected cohort of patients. The efficacy of adjuvant intracavitary therapy is as of yet undetermined, though developments in delivery techniques are promising. Likewise further developments of laser technology are anticipated to further expand the role of URS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11934-021-01065-7","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T09:26:41Z","timestamp":1633685201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Role of Ureteroscopy in Treatment of Upper Tract Urothelial Carcinoma"],"prefix":"10.1007","volume":"22","author":[{"given":"Jeremy","family":"Ng Chieng Hin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinul","family":"Hettiarachchilage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gravestock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar K.","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Veeratterapillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"5","key":"1065_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.21037\/tau.2016.03.23","volume":"5","author":"T Szarvas","year":"2016","unstructured":"Szarvas T, Modos O, Horvath A, et al. Why are upper tract urothelial carcinoma two different diseases? Transl Androl Urol. 2016;5(5):636\u201347.","journal-title":"Transl Androl Urol."},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OTT.S225301","volume":"13","author":"JJ Leow","year":"2020","unstructured":"Leow JJ, Liu Z, Tan TW, et al. Optimal management of upper tract urothelial carcinoma: current perspectives. Onco Targets Ther. 2020;13:1\u201315.","journal-title":"Onco Targets Ther."},{"issue":"1","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupret","year":"2021","unstructured":"Roupret M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 update. Eur Urol. 2021;79(1):62\u201379.","journal-title":"Eur Urol."},{"key":"1065_CR4","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Int J Surg 2010; doi:https:\/\/doi.org\/10.1016\/j.ijsu.2010.02.007","DOI":"10.1016\/j.ijsu.2010.02.007"},{"issue":"4","key":"1065_CR5","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/j.clgc.2018.01.015","volume":"16","author":"BM Browne","year":"2018","unstructured":"Browne BM, Stensland KD, Moynihan MJ, et al. An analysis of staging and treatment trends for upper tract urothelial carcinoma in the National Cancer Database. Clin Genitourin Cancer. 2018;16(4):e743\u201350.","journal-title":"Clin Genitourin Cancer."},{"issue":"6","key":"1065_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00345-018-2506-1","volume":"37","author":"A Upfill-Brown","year":"2019","unstructured":"Upfill-Brown A, Lenis AT, Faiena I, et al. Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. World J Urol. 2019;37(6):1157\u201364.","journal-title":"World J Urol."},{"issue":"6","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.urology.2005.12.034","volume":"67","author":"M Roupret","year":"2006","unstructured":"Roupret M, Hupertan V, Traxer O, et al. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology. 2006;67(6):1181\u20137.","journal-title":"Urology."},{"issue":"2","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1464-410X.2008.07535.x","volume":"102","author":"SM Lucas","year":"2008","unstructured":"Lucas SM, Svatek RS, Olgin G, et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int. 2008;102(2):172\u20136.","journal-title":"BJU Int."},{"issue":"5","key":"1065_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1089\/end.2010.0396","volume":"25","author":"C Gurbuz","year":"2011","unstructured":"Gurbuz C, Youssef RF, Shariat SF, et al. The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol. 2011;25(5):775\u20139.","journal-title":"J Endourol."},{"issue":"11","key":"1065_CR10","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1464-410X.2012.11066.x","volume":"110","author":"M Grasso","year":"2012","unstructured":"Grasso M, Fishman AI, Cohen J, et al. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. 2012;110(11):1618\u201326.","journal-title":"BJU Int."},{"issue":"11","key":"1065_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/j.1464-410X.2012.11169.x","volume":"110","author":"ML Cutress","year":"2012","unstructured":"Cutress ML, Stewart GD, Wells-Cole S, et al. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. 2012;110(11):1608\u201317.","journal-title":"BJU Int."},{"key":"1065_CR12","doi-asserted-by":"crossref","unstructured":"Murray K, Winer A, Bagrodia A, et al. Endoscopic management for upper tract urothelial cancer (UTUC) compared to immediate nephroureterectomy: survival outcomes in seer database and cancer center cohort. Journal of Urology. 2015;193(4).","DOI":"10.1016\/j.juro.2015.02.214"},{"key":"1065_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.urology.2016.05.033","volume":"95","author":"G Vemana","year":"2016","unstructured":"Vemana G, Kim EH, Bhayani SB, et al. Survival Comparison between endoscopic and surgical management for patients with upper tract urothelial cancer: a matched propensity score analysis using surveillance, epidemiology and end results-Medicare data. Urology. 2016;95:115\u201320.","journal-title":"Urology."},{"key":"1065_CR14","doi-asserted-by":"crossref","unstructured":"Bozzini G, Gastaldi C, Besana U, et al. Thulium-laser retrograde intra renal ablation (T-RIRA) of upper urinary tract transitional cell carcinoma: an ESUT study. Minerva Urol Nefrol. 2020.","DOI":"10.23736\/S2724-6051.20.03689-9"},{"issue":"1","key":"1065_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0302-2838(02)00220-8","volume":"42","author":"E Deligne","year":"2002","unstructured":"Deligne E, Colombel M, Badet L, et al. Conservative management of upper urinary tract tumors. Eur Urol. 2002;42(1):43\u20138.","journal-title":"Eur Urol."},{"issue":"5","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.juro.2007.01.006","volume":"177","author":"AE Krambeck","year":"2007","unstructured":"Krambeck AE, Thompson RH, Lohse CM, et al. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. The Journal of urology. 2007;177(5):1721\u20136.","journal-title":"The Journal of urology"},{"issue":"9","key":"1065_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1089\/end.2006.9922","volume":"21","author":"SJ Sowter","year":"2007","unstructured":"Sowter SJ, Ilie CP, Efthimiou I, et al. Endourologic management of patients with upper-tract transitional-cell carcinoma: long-term follow-up in a single center. J Endourol. 2007;21(9):1005\u20139.","journal-title":"J Endourol."},{"issue":"4","key":"1065_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.urology.2007.11.018","volume":"71","author":"RH Thompson","year":"2008","unstructured":"Thompson RH, Krambeck AE, Lohse CM, et al. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology. 2008;71(4):713\u20137.","journal-title":"Urology."},{"issue":"3","key":"1065_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/end.2008.0251","volume":"23","author":"RW Pak","year":"2009","unstructured":"Pak RW, Moskowitz EJ, Bagley DH, et al. What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol. 2009;23(3):341\u20136.","journal-title":"J Endourol."},{"issue":"1","key":"1065_CR20","first-page":"33","volume":"5","author":"G Nita","year":"2012","unstructured":"Nita G, Georgescu D, Multescu R, et al. Prognostic factors in laser treatment of upper urinary tract urothelial tumours. J Med Life. 2012;5(1):33\u20138.","journal-title":"J Med Life."},{"key":"1065_CR21","doi-asserted-by":"crossref","unstructured":"Vanacore D, Sanguedolce F, Montano B, et al. Evolving techniques of endoscopic UTUC management: optimising outcomes with the appropriate use of latest technologies. Journal of Urology. 2020;203.","DOI":"10.1097\/JU.0000000000000849.01"},{"key":"1065_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.urology.2018.05.042","volume":"121","author":"KB Scotland","year":"2018","unstructured":"Scotland KB, Kleinmann N, Cason D, et al. Ureteroscopic management of large >\/=2 cm upper tract urothelial carcinoma: a comprehensive 23-year experience. Urology. 2018;121:66\u201373.","journal-title":"Urology."},{"key":"1065_CR23","doi-asserted-by":"crossref","unstructured":"Defidio LD, De Dominicis M, Calarco A, et al. Is it possible and safe to treat endoscopically upper tract urothelial carcinoma larger than one centimeter? European Urology Supplements. 2018;17(4).","DOI":"10.1016\/S1569-9056(18)32482-5"},{"issue":"3","key":"1065_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/end.2017.0915","volume":"32","author":"G Musi","year":"2018","unstructured":"Musi G, Mistretta FA, Marenghi C, et al. Thulium laser treatment of upper urinary tract carcinoma: a multi-institutional analysis of surgical and oncological outcomes. J Endourol. 2018;32(3):257\u201363.","journal-title":"J Endourol."},{"issue":"11","key":"1065_CR25","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1089\/end.2019.0308","volume":"33","author":"L Defidio","year":"2019","unstructured":"Defidio L, Antonucci M, De Dominicis M, et al. Thulium-Holmium:YAG duo laser in conservative upper tract urothelial cancer treatment: 13 years experience from a Tertiary National Referral Center. J Endourol. 2019;33(11):902\u20138.","journal-title":"J Endourol."},{"key":"1065_CR26","doi-asserted-by":"crossref","unstructured":"\u2022 Scotland KB, Hubbard L, Cason D, et al. Long term outcomes of ureteroscopic management of upper tract urothelial carcinoma. Urol Oncol. 2020;38(11):850 e17- e26.\u00a0Recent large study with long-term outcomes of ureterosopic management of upper tract tumours.","DOI":"10.1016\/j.urolonc.2020.06.027"},{"issue":"5","key":"1065_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","volume":"110","author":"ML Cutress","year":"2012","unstructured":"Cutress ML, Stewart GD, Zakikhani P, et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012;110(5):614\u201328.","journal-title":"BJU Int."},{"key":"1065_CR28","unstructured":"Mohapatra A, Strope SA, Vetter J, et al. Importance of long-term followup after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management. Can Urol Assoc J. 2017;11(9)."},{"issue":"9","key":"1065_CR29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00345-015-1753-7","volume":"34","author":"L Villa","year":"2016","unstructured":"Villa L, Cloutier J, Letendre J, et al. Early repeated ureteroscopy within 6\u20138 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol. 2016;34(9):1201\u20136.","journal-title":"World J Urol."},{"issue":"1","key":"1065_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.juro.2017.07.088","volume":"199","author":"L Villa","year":"2018","unstructured":"\u2022 Villa L, Haddad M, Capitanio U, et al. Which patients with upper tract urothelial carcinoma can be safely treated with flexible ureteroscopy with Holmium:YAG laser photoablation? Long-Term Results from a High Volume Institution. J Urol. 2018;199(1):66\u201373.\u00a0Recent paper on endoscopic management of upper tract tumours. Study showed that tumour size greater than 1 cm and multifocality did not increase the risk of tumour progression.","journal-title":"J Urol."},{"key":"1065_CR31","doi-asserted-by":"crossref","unstructured":"Shvero A, Zilberman D, Laufer M, et al. Endoscopic treatment for upper urinary tract urothelial carcinoma-does size matter? J Urol. 2019;201(4).","DOI":"10.1097\/01.JU.0000556422.87431.3f"},{"issue":"3","key":"1065_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/bju.13935","volume":"120","author":"M Marchioni","year":"2017","unstructured":"Marchioni M, Primiceri G, Cindolo L, et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int. 2017;120(3):313\u20139.","journal-title":"BJU Int."},{"issue":"2","key":"1065_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5173\/ceju.2015.537","volume":"68","author":"L Dolowy","year":"2015","unstructured":"Dolowy L, Krajewski W, Dembowski J, et al. The role of lasers in modern urology. Cent European J Urol. 2015;68(2):175\u201382.","journal-title":"Cent European J Urol."},{"issue":"3","key":"1065_CR34","first-page":"147","volume":"83","author":"L Defidio","year":"2011","unstructured":"Defidio L, De Dominicis M, Di Gianfrancesco L, et al. First collaborative experience with thulium laser ablation of localized upper urinary tract urothelial tumors using retrograde intra-renal surgery. Arch Ital Urol Androl. 2011;83(3):147\u201353.","journal-title":"Arch Ital Urol Androl."},{"issue":"Suppl 4","key":"1065_CR35","doi-asserted-by":"publisher","first-page":"S398","DOI":"10.21037\/tau.2019.08.01","volume":"8","author":"P Kronenberg","year":"2019","unstructured":"Kronenberg P, Traxer O. The laser of the future: reality and expectations about the new thulium fiber laser-a systematic review. Transl Androl Urol. 2019;8(Suppl 4):S398\u2013417.","journal-title":"Transl Androl Urol."},{"issue":"Suppl 1","key":"1065_CR36","first-page":"S1","volume":"46","author":"M Schembri","year":"2020","unstructured":"Schembri M, Sahu J, Aboumarzouk O, et al. Thulium fiber laser: the new kid on the block. Turk J Urol. 2020;46(Suppl 1):S1\u201310.","journal-title":"Turk J Urol"},{"key":"1065_CR37","doi-asserted-by":"crossref","unstructured":"\u2022 Martov AG, Ergakov DV, Solomatnikov I, et al. Thulium superpulse fiber laser (TSPFL) in the endourological management of upper urinary tract urothelial carcinoma (UTUC). Journal of Endourology. 2018;32.\u00a0Recent paper using thulium fiber laser on endourological management of upper tract tumours.","DOI":"10.1016\/S1569-9056(19)31633-1"},{"key":"1065_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.urology.2020.09.036","volume":"147","author":"J Linehan","year":"2021","unstructured":"Linehan J, Schoenberg M, Seltzer E, et al. Complications associated with ureteroscopic management of upper tract urothelial carcinoma. Urology. 2021;147:87\u201395.","journal-title":"Urology."},{"key":"1065_CR39","doi-asserted-by":"crossref","unstructured":"Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol. 2000;38(6):701-4;discussion 5.","DOI":"10.1159\/000020365"},{"key":"1065_CR40","doi-asserted-by":"crossref","unstructured":"Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol. 2003;169(3):925-9; discussion 9-30.","DOI":"10.1097\/01.ju.0000050242.68745.4d"},{"issue":"1","key":"1065_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/01.ju.0000132128.79974.db","volume":"172","author":"J Palou","year":"2004","unstructured":"Palou J, Piovesan LF, Huguet J, et al. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol. 2004;172(1):66\u20139.","journal-title":"J Urol."},{"issue":"4","key":"1065_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1442-2042.2006.01312.x","volume":"13","author":"Y Kojima","year":"2006","unstructured":"Kojima Y, Tozawa K, Kawai N, et al. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guerin therapy. Int J Urol. 2006;13(4):340\u20134.","journal-title":"Int J Urol."},{"issue":"1","key":"1065_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","volume":"73","author":"AR Rastinehad","year":"2009","unstructured":"Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy? Urology. 2009;73(1):27\u201331.","journal-title":"Urology."},{"issue":"5","key":"1065_CR44","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","volume":"60","author":"G Giannarini","year":"2011","unstructured":"Giannarini G, Kessler TM, Birkhauser FD, et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol. 2011;60(5):955\u201360.","journal-title":"Eur Urol."},{"issue":"12","key":"1065_CR45","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1089\/end.2012.0229","volume":"26","author":"EY Shapiro","year":"2012","unstructured":"Shapiro EY, Lipsky MJ, Cha DY, et al. Outcomes of intrarenal Bacillus Calmette-Guerin\/interferon-alpha2B for biopsy-proven upper-tract carcinoma in situ. J Endourol. 2012;26(12):1645\u201350.","journal-title":"J Endourol."},{"issue":"4","key":"1065_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12032-018-1102-y","volume":"35","author":"H Horiguchi","year":"2018","unstructured":"Horiguchi H, Yoneyama T, Hatakeyama S, et al. Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol. 2018;35(4):41.","journal-title":"Med Oncol."},{"issue":"2","key":"1065_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/07357907.2018.1430815","volume":"36","author":"I Tomisaki","year":"2018","unstructured":"Tomisaki I, Kubo T, Minato A, et al. Efficacy and tolerability of Bacillus Calmette-Guerin therapy as the first-line therapy for upper urinary tract carcinoma in situ. Cancer Invest. 2018;36(2):152\u20137.","journal-title":"Cancer Invest."},{"issue":"7","key":"1065_CR48","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","volume":"37","author":"B Foerster","year":"2019","unstructured":"Foerster B, D\u2019Andrea D, Abufaraj M, et al. Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature. Urol Oncol. 2019;37(7):430\u20136.","journal-title":"Urol Oncol."},{"key":"1065_CR49","unstructured":"Gallioli A, Boissier R, Territo A, et al. Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre"},{"key":"1065_CR50","doi-asserted-by":"crossref","unstructured":"Balasubramanian A, Metcalfe M, Wagenheim G, et al. Results of second line topical therapy for upper tract urothelial carcinoma (UTUC). Eur Urol Suppl. 2017;16(3).","DOI":"10.1016\/S1569-9056(17)31090-4"},{"issue":"6","key":"1065_CR51","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","volume":"21","author":"N Kleinmann","year":"2020","unstructured":"\u2022\u2022 Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. The Lancet Oncology. 2020;21(6):776\u201385.\u00a0Recent study with promising results on primary chemoablation of low-grade upper tract tumours with intracavitary mitomycin containing reverse thermal gel.","journal-title":"The Lancet. Oncology"},{"issue":"1\u20132","key":"1065_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijpharm.2016.08.061","volume":"513","author":"AA Barros","year":"2016","unstructured":"Barros AA, Browne S, Oliveira C, et al. Drug-eluting biodegradable ureteral stent: new approach for urothelial tumors of upper urinary tract cancer. Int J Pharm. 2016;513(1\u20132):227\u201337.","journal-title":"Int J Pharm."},{"issue":"10","key":"1065_CR53","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/j.1464-410X.2012.11341.x","volume":"110","author":"BP Rai","year":"2012","unstructured":"Rai BP, Shelley M, Coles B, et al. Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. BJUI. 2012;110(10):1426\u201335.","journal-title":"BJUI"},{"issue":"5","key":"1065_CR54","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.urology.2013.12.019","volume":"83","author":"RA Chapman","year":"2014","unstructured":"Chapman RA, Somani BK, Robertson A, et al. Decreasing cost of flexible ureterorenoscopy: single use laser fiber cost analysis. Urology. 2014;83(5):1003\u20135.","journal-title":"Urology"},{"issue":"3","key":"1065_CR55","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.urology.2010.12.073","volume":"78","author":"BK Somani","year":"2011","unstructured":"Somani BK, Robertson A, Kata SG. Decreasing the cost of flexible ureterorenoscopic procedures. Urology. 2011;78(3):528\u201330.","journal-title":"Urology"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-021-01065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-021-01065-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-021-01065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T10:05:53Z","timestamp":1699610753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-021-01065-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s11934-021-01065-7","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"15 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jeremy Ng, Chieng Hin, Dinul Hettiarachchilage, Paul Gravestock, Bhavan Rai, Bhaskar K Somani, and Rajan Veeratterapillay have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The tables and figures included within are original and created by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"49"}}